Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023;14:1071983. https://doi.org/10.3389/fimmu.2023.1071983.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eshaq AM, Flanagan TW, Ba Abbad AA, Makarem ZAA, Bokir MS, Alasheq AK, et al. Immune checkpoint Inhibitor-Associated cutaneous adverse events: mechanisms of occurrence. Int J Mol Sci. 2024;26(1). https://doi.org/10.3390/ijms26010088.

Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint Blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001.

Article  CAS  PubMed  Google Scholar 

Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365. https://doi.org/10.1016/j.intimp.2024.113365.

Article  CAS  PubMed  Google Scholar 

Rodríguez G, de Montes AL, Spencer LM, Chimeric Antigen Receptor T, Cells. Immunotherapy for the treatment of leukemia, lymphoma, and myeloma. Mol Cancer Ther. 2023;22(11):1261–9. https://doi.org/10.1158/1535-7163.Mct-23-0043.

Article  Google Scholar 

Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22(8):1875–84. https://doi.org/10.1158/1078-0432.Ccr-15-1433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-Cells for Cancer therapy. J Natl Cancer Inst. 2016;108(7). https://doi.org/10.1093/jnci/djv439.

Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106. https://doi.org/10.1016/j.pharmthera.2021.108106.

Article  CAS  PubMed  Google Scholar 

Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–62. https://doi.org/10.1016/s1470-2045(16)30030-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641–61. https://doi.org/10.1038/s41573-023-00709-2.

Article  CAS  PubMed  Google Scholar 

Lu W, Zhang H, Guo Q, Gou Z, Yao J. Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis. Front Pharmacol. 2023;14:1076473. https://doi.org/10.3389/fphar.2023.1076473.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–126. https://doi.org/10.1200/jco.21.01440.

Article  CAS  PubMed  Google Scholar 

Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-Cell therapies for cancer: A translational. Sci Rev Jama. 2024;332(22):1924–35. https://doi.org/10.1001/jama.2024.19462.

Article  CAS  Google Scholar 

June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. https://doi.org/10.1056/NEJMra1706169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5). https://doi.org/10.3390/cancers9050052.

Chen D, Hong R, Cao Y, Wu Q, Wang Y, Chen J, et al. Combined Wee1 and EGFR Inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma. Carcinogenesis. 2023;44(6):451–62. https://doi.org/10.1093/carcin/bgad038.

Article  CAS  PubMed  Google Scholar 

Li Y, Fu R, Jiang T, Duan D, Wu Y, Li C, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 2022;12:804212. https://doi.org/10.3389/fonc.2022.804212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant anaplastic thyroid Cancer. J Clin Oncol. 2018;36(1):7–13. https://doi.org/10.1200/jco.2017.73.6785.

Article  CAS  PubMed  Google Scholar 

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK Inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703. https://doi.org/10.1056/NEJMoa1210093.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus Trametinib versus Dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–9. https://doi.org/10.1093/annonc/mdx176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus Trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–16. https://doi.org/10.1016/s1470-2045(17)30679-4.

Article  CAS  PubMed  Google Scholar 

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384–8. https://doi.org/10.1001/jamaoncol.2017.5029.

Article  PubMed  Google Scholar 

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384–8. https://doi.org/10.1001/jamaoncol.2017.5029. 

Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al. Dabrafenib plus Trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53–64. https://doi.org/10.1016/s1470-2045(21)00578-7.

Article  CAS  PubMed  Google Scholar 

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541–53. https://doi.org/10.1016/s0140-6736(21)02175-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, hormone Receptor-Positive advanced breast Cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.

Article  PubMed  Google Scholar 

Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273–91. https://doi.org/10.1038/nrclinonc.2018.28.

Article  CAS  PubMed  Google Scholar 

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. https://doi.org/10.1056/NEJMoa1315226.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, et al. Long-term safety and efficacy of the PI3K inhibitor Copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362–71. https://doi.org/10.1002/ajh.25711.

Article  CAS  PubMed  Google Scholar 

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–55. https://doi.org/10.1182/blood-2018-05-850461.